These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 26237681)
1. Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway. Zoellner AK; Bayerl S; Hutter G; Zimmermann Y; Hiddemann W; Dreyling M Leuk Lymphoma; 2015; 56(12):3393-400. PubMed ID: 26237681 [TBL] [Abstract][Full Text] [Related]
2. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors. Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345 [TBL] [Abstract][Full Text] [Related]
3. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458 [TBL] [Abstract][Full Text] [Related]
5. CD79B limits response of diffuse large B cell lymphoma to ibrutinib. Kim JH; Kim WS; Ryu K; Kim SJ; Park C Leuk Lymphoma; 2016; 57(6):1413-22. PubMed ID: 26699656 [TBL] [Abstract][Full Text] [Related]
6. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism]. Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142 [TBL] [Abstract][Full Text] [Related]
7. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949 [TBL] [Abstract][Full Text] [Related]
8. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells. Zhu F; Guo H; Bates PD; Zhang S; Zhang H; Nomie KJ; Li Y; Lu L; Seibold KR; Wang F; Rumball I; Cameron H; Hoang NM; Yang DT; Xu W; Zhang L; Wang M; Capitini CM; Rui L Leukemia; 2019 Dec; 33(12):2898-2911. PubMed ID: 31123343 [TBL] [Abstract][Full Text] [Related]
9. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267 [TBL] [Abstract][Full Text] [Related]
10. Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma. Rodgers TD; Reagan PM Expert Opin Emerg Drugs; 2018 Jun; 23(2):111-122. PubMed ID: 29781323 [TBL] [Abstract][Full Text] [Related]
11. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620 [TBL] [Abstract][Full Text] [Related]
12. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398 [TBL] [Abstract][Full Text] [Related]
13. Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT. Paul J; Soujon M; Wengner AM; Zitzmann-Kolbe S; Sturz A; Haike K; Keng Magdalene KH; Tan SH; Lange M; Tan SY; Mumberg D; Lim ST; Ziegelbauer K; Liu N Cancer Cell; 2017 Jan; 31(1):64-78. PubMed ID: 28073005 [TBL] [Abstract][Full Text] [Related]
14. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Krause G; Hassenrück F; Hallek M Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412 [TBL] [Abstract][Full Text] [Related]
15. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma. He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096 [TBL] [Abstract][Full Text] [Related]
16. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies. Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942 [No Abstract] [Full Text] [Related]
17. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1. Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668 [TBL] [Abstract][Full Text] [Related]
18. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343 [TBL] [Abstract][Full Text] [Related]
19. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251 [TBL] [Abstract][Full Text] [Related]
20. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]